{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-002463","form_type":"8-K","ticker":null,"cik":"0001797336","company_name":"Ayala Pharmaceuticals, Inc.","filed_at":"2023-01-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.578181+00:00","generated_at":"2026-06-20T09:38:33.808112+00:00","sec_items":["2.01","3.01","3.03","5.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ayala completes merger with Advaxis; becomes wholly-owned subsidiary; shares converted at 0.1874 ratio","bullets":["Merger closed Jan 19, 2023; each share of Ayala common stock converted into 0.1874 shares of Advaxis common stock.","Ayala becomes wholly-owned subsidiary of Advaxis; Ayala common stock to be delisted from Nasdaq.","Board of directors resigned; Ken Berlin appointed sole director and CEO, Andrew Gutierrez CMO, Igor Gitelman CFO.","ATM equity facility with Jefferies terminated effective ten trading days after Jan 13, 2023; no penalties.","Ayala to file Form 15 to suspend reporting obligations under Exchange Act."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-002463","json":"https://secwatch.observer/filing/0001493152-23-002463.json","markdown":"https://secwatch.observer/filing/0001493152-23-002463.md","text":"https://secwatch.observer/filing/0001493152-23-002463.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T09:38:33.808112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"157454882a","claim":"Roni Mamluk resigned as director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"each of Vered Bisker-Leib, Ph.D., Murray A. Goldberg, Roni Mamluk, Ph.D., David Sidransky, M.D. and Robert Spiegel, M.D. resigned as members of the board of directors of Ayala and Kenneth A. Berlin became the sole director of Ayala.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"39c93ac742","claim":"Kenneth A. Berlin was appointed as President and Chief Executive Officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Kenneth A. Berlin was appointed President and Chief Executive Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"419ecf55c0","claim":"Kenneth A. Berlin was appointed as director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Kenneth A. Berlin became the sole director of Ayala","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"4818740ce6","claim":"Murray A. Goldberg resigned as director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"each of Vered Bisker-Leib, Ph.D., Murray A. Goldberg, Roni Mamluk, Ph.D., David Sidransky, M.D. and Robert Spiegel, M.D. resigned as members of the board of directors of Ayala and Kenneth A. Berlin became the sole director of Ayala.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"49fe4e62be","claim":"Vered Bisker-Leib resigned as director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"each of Vered Bisker-Leib, Ph.D., Murray A. Goldberg, Roni Mamluk, Ph.D., David Sidransky, M.D. and Robert Spiegel, M.D. resigned as members of the board of directors of Ayala and Kenneth A. Berlin became the sole director of Ayala.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"6b7c5422cd","claim":"Yossi Maimon departed as other_named_officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Immediately after the Effective Time, Roni Mamluk, Ph.D. and Yossi Maimon ceased to be officers of Ayala","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"}],"fact_type":"executive_change"},{"claim_id":"7b2084378c","claim":"Igor Gitelman was appointed as Chief Financial Officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Igor Gitelman was appointed Chief Financial Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"8d963fedbf","claim":"Roni Mamluk departed as other_named_officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Immediately after the Effective Time, Roni Mamluk, Ph.D. and Yossi Maimon ceased to be officers of Ayala","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"ceased"}],"fact_type":"executive_change"},{"claim_id":"a7a8e5ad8c","claim":"Robert Spiegel resigned as director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"each of Vered Bisker-Leib, Ph.D., Murray A. Goldberg, Roni Mamluk, Ph.D., David Sidransky, M.D. and Robert Spiegel, M.D. resigned as members of the board of directors of Ayala and Kenneth A. Berlin became the sole director of Ayala.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"b62ef766ca","claim":"Andrew A. Gutierrez was appointed as Chief Medical Officer at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"Andrew A. Gutierrez, M.D., Ph.D., was appointed the Chief Medical Officer","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"},{"claim_id":"fed420b12e","claim":"David Sidransky resigned as director at Ayala Pharmaceuticals, Inc..","evidence_excerpt":"each of Vered Bisker-Leib, Ph.D., Murray A. Goldberg, Roni Mamluk, Ph.D., David Sidransky, M.D. and Robert Spiegel, M.D. resigned as members of the board of directors of Ayala and Kenneth A. Berlin became the sole director of Ayala.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"407034d808d96bc21391a3e987f7bc18c105471b","claim":"Ayala Pharmaceuticals, Inc. underwent a change of control involving Advaxis, Inc. (closed 2023-01-19).","evidence_excerpt":"On January 19, 2023 (the “Closing Date”), pursuant to the Merger Agreement, Merger Sub merged with and into Ayala, with Ayala continuing as the surviving company and a wholly-owned subsidiary of Advaxis (the “Merger”).","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1797336/000149315223002463/0001493152-23-002463-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"change of control"},{"label":"Counterparty","value":"Advaxis, Inc."},{"label":"Closing","value":"2023-01-19"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}